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Abstract 
Increasing evidence suggests that cancer stem cells (CSCs) are a key occurrence in the process of many human 
cancers. Lung cancer is the most common aggressive malignancy and cause of cancer death worldwide. The research 
on lung cancer stem cells has been highlighted for many years. Lung CSCs seem to play a major role in lung cancer 
metastasis, drug resistance and tumour-self-renewal. MicroRNAs (miRNAs), a class of newly emerging small noncod-
ing RNAs that act as post-transcriptional regulators of gene expression, have been demonstrated to serve as a vital 
player in fine-tuning a number of biological activities ranging from embryogenesis to programmed cell death as well 
as tumourigenesis. In recent years, several miRNAs have been highlighted to be specifically expressed in CSCs. The 
miRNA profile of CSCs is remarkably different from non-stem cancer cells. As such, many miRNAs have been shown to 
regulate self-renewal and differentiation properties of CSCs. In this review, we present the latest findings on miRNAs 
that regulate the tumour microenvironment of lung CSCs with the goal to prompt the development of novel thera-
peutic strategies for patients with lung cancer.
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Background
Lung cancer is the leading cause of cancer deaths and the 
most common aggressive carcinoma worldwide (Ferlay 
et  al. 2010; Papagiannis 2004). The research on onco-
therapy has been highlighted for more than half a cen-
tury. Accurately understanding the molecular biology of 
cancer is the only possibility for conquering lung cancer. 
During the past 20 years, the discovery and study of miR-
NAs has provided a new approach for the treatment of 
cancer. Since Lee et al. (1993) and Reinhart et al. (2000) 
first identified miRNAslin-4 and let-7controlling the 
developmental timing in nematode Caenorhabditisele-
gans, extensive studies have been conducted to discover 
the functional role of miRNAs in multiple biological 
activities, ranging from embryonic development to cell 
death (Fabian and Sonenberg 2012; Pauli et al. 2011; Rinn 
and Chang 2012), and from cancer formation to its devel-
opment (Li et al. 2009; Wang et al. 2013b; Ohashi et al. 
2011; Pang et al. 2010c; Rachagani et al. 2010; Kurisetty 
et al. 2014; Serpico et al. 2014; D’Ippolito and Iorio 2013).
Since Mackillop (Mackillop et  al. 1983) first put for-
ward the hypothesis of cancer stem cell theory, the 
overwhelming mass of research has infiltrated into the 
characterization of cancer stem cells (CSCs) from differ-
ent tumours (Chhabra and Saini 2014). The cancer stem 
cell hypothesis is based on a theory that cancer has a 
hierarchical cell structure in which only a subpopulation 
of cells, termed cancer stem cells (CSCs), which have the 
ability to regulate self-renewal and differentiation of can-
cer cells, are able to initiate tumour formation. In addi-
tion, they also fine-tune tumour metastasis by altering 
genetic signalling pathways (Pang et al. 2010a; Hermann 
et al. 2007). Lung CSCs, which have the characteristics of 
self-renewal and differentiation, were first isolated from 
the junction between the rat bronchioles and alveolar 
ducts by Kim in 2005.
miRNAs are short (20- to 24-nucleotide), small and 
non-coding single-stranded RNA molecules that can 
inhibit gene expression by conducting target mRNA 
degradation or translational repression. Its molecular 
mechanism is that primary miRNAs (primiRNAs), which 
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are transcribed by RNA polymerase II or III with 5′-end 
caps and 3′-end poly-A tails (Borchert et  al. 2006; Lee 
et  al. 2004; Cai et  al. 2004), bind to the 3′-untraslated 
regions (3′UTRs) or the open reading frames of target 
genes to influence expression of mRNA. miRNAs regu-
late gene expression. It has been demonstrated that miR-
NAs inhibit gene translation in a proliferating state but 
stimulate it in a quiescent state (Vasudevan et  al. 2007; 
Bartel 2004; Garzon et  al. 2009). It can be summarized 
that miRNAs participate in a series of biological pro-
cesses including cell proliferation, apoptosis, the immune 
response and differentiation of CSCs (Dumortier et  al. 
2013; Hwang and Mendell 2006; Chivukula and Mendell 
2008; Esau et al. 2004; Zhao et al. 2010; DeSano and Xu 
2009; Perera and Ray 2007) by intervening with biological 
signals of transcription, nuclear processing, exportation, 
and cytoplasmic processing, as well as inhibiting or acti-
vation translation (Bartel 2004; Garzon et al. 2007, 2009; 
Liu and Tang 2011). Abundant expression of miRNAs has 
also been found in CSCs. Since Lee et al. (1993), Reinhart 
et al. (2000) first identified miRNAs regulating stem cells 
in Caenorhabditiselegans, cancer research has stepped 
into a new stage in recent years. If the CSC hypothesis 
is true, then deletion of CSCs would be a perfect treat-
ment, and the aberrant expression profile of miRNAs 
may be the cause of the initiation and development of the 
tumour (Lobo et al. 2007). Therefore, regulating expres-
sion of miRNAs would be a new target to treat cancer. 
This aspect, however, needs further study.
miRNAs IN LUNG CSCs
An increasing number of miRNAs have been confirmed 
to be involved in self-renewal and metabolism of lung 
CSCs. miRNA-145 was found to be expressed at low 
levels in lung adenocarcinoma (LAD)-associated CSCs 
and was further validated to inhibit the proliferation of 
LAD-CSCs and be negatively correlated with the levels 
of Oct4/Sox2/Fascin1 in LAD patient specimens (Chiou 
et al. 2012; Zhang et al. 2011; Hu et al. 2014). In two other 
studies on lung adenocarcinoma CSC, let-7and miR-31 
were significantly down-regulated in side population (SP) 
cells, which are an enriched source of CSCs, compared 
to non-SP cells (Hua et  al. 2012). Interestingly, these 
two miRNAs play opposing roles to maintain a balance 
between differentiation and quiescence of LAD-CSCs. 
A previous study showed that miRNA-200b is signifi-
cantly down-regulated in CD133+/CD326+cells, which 
exhibit characteristics of CSCs derived from docetaxel-
resistant LAD cells. These findings strongly suggest that 
aberrantly expressed miRNAs, such as miR-29ab, miR-
183, and miR-127-3P, play significant roles in regulating 
the CD133+/CD326+ subpopulation of cells (Lin et  al. 
2012). Therefore, miRNAs could substantially affect the 
biobehaviours of LCSCs, including cell cycle, prolifera-
tion, apoptosis, immune response and differentiation, by 
controlling the signalling pathways of LCSCs. Here, we 
present the latest findings on miRNAs that regulate the 
tumour microenvironment of lung CSCs to prompt the 
development of novel therapeutic strategies for patients 
with lung cancer (Table 1). Figure 1 shows the potential 
therapeutics of miRNAs in LCSCs.
miRNA‑145 regulates lung CSCs
miRNA-145 is an important regulator of tumourigen-
esis. Previous research by Cho WC demonstrated that 
miRNA-145 inhibited cell proliferation of human lung 
adenocarcinoma by targeting EGFR and NUDT1 (Cho 
et  al. 2011). Lu et  al. (2014) further found that mir-
RNA-145 functions as a tumour suppressor and targets 
two oncogenes, ANGPT2 and NEDD9, in renal cell 
carcinoma. In recent years, it has been shown that mir-
RNA-145 is down-regulated in lung adenocarcinoma 
tissues and negatively correlates with the expression of 
Oct4 (Yin et al. 2011), which is expressed in lung CSCs 
(CD133+cells) (Hu et  al. 2014). The precise molecular 
mechanism of mirRNA-145 in lung CSCs is not known. 
A previous study indicated that miRNA-145 reduced the 
capacity of proliferation, invasion and tumour sphere 
growth in lung adenocarcinoma-initiating cells. Epithe-
lial-mesenchymal transition (EMT), which regulates a 
dedifferentiation programme that converts adherent epi-
thelial cells to individual migratory cells, plays an impor-
tant role in regulating embryonic development, cancer 
migration, and tumour metastasis (Kalluri and Weinberg 
2009; Thiery 2002), which is similar to CSCs (Pirozzi 
et  al. 2011). Dai et  al. (2013) confirmed that the EMT 
process of colorectal cancer cells was regulated by Oct4, 
an important transcriptional factor that has been pro-
posed as a biomarker of cancer-initiating cells (CICs). 
Hu et  al. (2014) further verified the amazing effect of 
miR-145 on properties of lung CSCs and EMT in  vivo 
by regulating Oct4. It has been reported that cationic 
polyurethane-short branch polyethylenimine (PU-PEI) 
exhibits high transfection efficiency with relatively low 
cytotoxicity (Hung et  al. 2009; Liu et  al. 2009) and has 
been shown to be a deliverer for overexpression of Oct4 
and SirT1 in the process of reprogramming aged retinal 
pigmented epithelium cells into progenitor-like cells and 
rescuing light-induced retinal cell loss and dysfunction 
(Peng et al. 2011). Guang-Yuh and his colleagues found 
that LAD patients with a microRNA-145low, Oct4high, 
Sox2high, or Fascin1high phenotype had a poor prog-
nosis and outcome, and microRNA-145 was proven 
to be the most relevant marker (Chiou et  al. 2012). As 
a vehicle formicroRNA-145 delivery, PU-PEI mediates 
miR-145 overexpression and inhibits the properties of 
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LAD-CSCs by repressing its downstream targets, Oct4, 
Sox2, and Fascin1 (Chiou et al. 2012), which provides a 
novel miRNA-based approach for the treatment of LAD 
by artificially enhanced expression of microRNA-145 
(Fig. 2).
MicroRNA‑31 and let‑7 regulate lung CSCs
Encoded by a single genomic locus, microRNA-31 is 
expressed in a variety of tissues and cell types (Grim-
son et al. 2007; Landgraf et al. 2007). Altered expression 
of miR-31 has been verified in various human tumours 
Fig. 1 The different miRNAs regulate properties of lung cancer stem cells (LCSCs). By targeting a variety of downstream signalling pathways, several 
miRNAsact synergistically to regulate several key biological properties of LCSCs including differentiation, relapse, regeneration, metastasis, chemore-
sistance and apoptosis
Fig. 2 miR-145 is transcribed by RNA polymerase II (Pol II) into long primary miRNA145 transcripts, which are cleaved in the nucleus by the RNase III 
enzyme Drosha, resulting in a hairpin precursor form called pre-miRNA. Pre-miRNA is exported from the nucleus to the cytoplasmby exportin 5 and 
is further processed by the enzyme Dicer, which produces a transient miRNA duplex that includes a mature miR-145. miR-145 targets sites of the 
3′UTRs of Oct4, Sox2, and Fascin1 and represses Oct4, Sox2, and Fascin1 to inhibit the properties of LCSCs
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(Valastyan and Weinberg 2010). It is reported that miR-
31 levels are inversely associated with the propensity 
to suffer metastatic relapse in primary human breast 
tumours (Valastyan et al. 2009b). Similarly, down-regu-
lation of miR-31 was observed in human bladder carci-
nomas with an invasive phenotype (Wszolek et al. 2011). 
Valastyan et  al. (2009a) has stated that miR-31 impairs 
more than three distinct steps of the invasion–metasta-
sis cascade: local invasion, one or more early post-intra-
vasation events (intraluminal viability, extravasation, 
and/or initial survival in the parenchyma of distant tis-
sues), and metastatic colonization (the outgrowth of 
micrometastases into macroscopic secondary lesions). 
The let-7 family, one of the most highly up-regulated 
families of miRNAs, consists of 12 members located in 
genomic locations frequently deleted in human cancers 
(Calin et  al. 2004). The let-7 family targets several key 
genes in the PI3K/AKT/insulin pathway during cardiac 
maturation (Kuppusamy et al. 2015). The early research 
on let-7 in the field is about energy metabolism (Zhu 
et al. 2011; Frost and Olson 2011). In recent years, it has 
been reported that let-7 was down-regulated in several 
cancers (Johnson et al. 2005; Mayr et al. 2007; Sampson 
et al. 2007). Johnson et al. (2005) found that expression 
of let-7 RNA is reduced in non-small cell lung can-
cer patients and is associated with poor prognosis. In 
addition, overexpression of let-7 reduces tumour bur-
den in a K-Ras murine lung cancer model (Sampson 
et  al. 2007). SP cells are a rare cell population that are 
an enriched source of stem cells in some normal tissue 
and intumours, such as glioma, colorectal, ovarian can-
cer and lung cancer tumours (Kondo et al. 2004; Brown 
et  al. 2007; Szotek et  al. 2006; Ho et  al. 2007; Larderet 
et  al. 2006). Under differentiating conditions, SP cells 
can differentiate into non-SP cells and lose their stem-
like properties (the ratio of SP gradually decreases with 
culture time) (Hua et  al. 2012). It has been confirmed 
that microRNA-31 and let-7 are significantly down-reg-
ulated in lung SP cells (lung CSCs). Interestingly, Hua 
et  al. (2012) found that low expression of let-7 was the 
key to the preservation of their ability to proliferate, and 
low expression of microRNA-31 was necessary for their 
undifferentiated status to persist. It can be confirmed 
that the reduced expression of let-7 and microRNA-
31were critical for SP cells to preserve their stemness. 
MicroRNA-31 acts as an oncogenic gene, while let-7 
functions as a lung cancer suppressor microRNA (John-
son et  al. 2007; Liu et  al. 2010), which suggests that 
miR-31 and let-7 have opposite functions on lung CSCs. 
Antisense oligonucleotide transfection experiments have 
supported this view by cell cycle research that showed 
that reduced miR-31 could inhibit cell proliferation by 
a cell cycle arrest in the G0/G1 phase, whereas reduced 
let-7 induced cell proliferation by accelerating the G1/S 
phase transition (Hua et  al. 2012; Fig.  3). As regulators 
for maintaining the balance between differentiation and 
quiescence for SP cells, let-7 and microRNA-31 would be 
novel endogenous lung CSC targets to treat lung cancer.
Fig. 3 As is shown in a, let-7 and miR-31 are regulators for maintaining the balance between differentiation and quiescence for LCSCs. Cell cycle 
studies further revealed that increasing miR-31 could enhance the proliferation of LCSCs by speeding up the cell cycle in the G0/G1 phase, whereas 
reduced let-7 induced cell proliferation of LCSCs by accelerating the G1/Sphase transition (b)
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miRNA‑34a regulates lung CSCs
The miRNA-34 family, which is composed of miR-34a, 
miR-34b, and miR-34c, is confirmed to be involved in the 
p53 and Notch signalling pathways (Shi et al. 2014; Bom-
mer et  al. 2007; Li et  al. 2009; Pang et  al. 2010b; Balca-
Silva et  al. 2012; Fig.  4). Pang et  al. have demonstrated 
that miRNA-34a binds to the 3′-untranslated regions of 
Notch1 and Jagged1. miRNA-34a is a tumour suppres-
sor gene (Chen and Hu 2012) and inhibits abnormal 
cell growth, such as that in pancreas, melanoma, lung, 
breast, prostate, osteosarcoma, and gliomatumours (He 
et al. 2009; Poellinger and Lendahl 2008; Yang et al. 2013; 
Liu and Tang 2011; Yan et al. 2012; Wiggins et al. 2010; 
Bandi and Vassella 2011). However, miR-34b/c, which 
has been identified in cases of malignant melanoma and 
glioma, may have the opposite function (Wu et al. 2013).
With the research on the CSC hypothesis, the miR-34 
family has now been shown to affect major properties 
of CSCs. Liu et  al. (2011) have shown that miRNA-34a 
can inhibit prostate CSCs by directly repressing CD44. 
In another instance, enforced expression ofmiR-34 
inhibited the self-renewal capacity of CD44C/CD133C 
pancreatic CSCs through the directdown-regula-
tionofBcl-2and Notch signalling pathways (Wang et  al. 
2006). Furthermore, miRNA-34a was demonstrated to 
inhibit NSCLC cell holoclone formation and clonogenic 
expansion in vitro and even to repress tumour regenera-
tion in vivo (Shi et al. 2014), which are due to its effects 
on stem-like NSCLC (NSCLC-CSCs). Further study veri-
fied that enhanced expression of miRNA-34a in CD44hi 
H460 cells greatly inhibited their tumour-regenerating 
activity. On the contrary, antagonists of miR-34a dra-
matically promoted tumour regeneration in CD44loH460 
cells. Similarly, these observations are confirmed in 
prostate and lung cancer (Wang et  al. 2013a). In addi-
tion, the lower expression of miR-34a was considered 
to be a key aetiologic factor contributing to the aggres-
sive behaviour of lung cancer stem cells (CSC), and thus, 
those features were mitigated by exogenous delivery and 
restoration of miR-34a activity (Basak et al. 2013). Taken 
together, as a regulator of the tumour-initiating capac-
ity in NSCLC-CSCs, restoration of miR-34 levels may 
be used as a cancer therapeutic by down-regulating the 
Notch family members or target genes. The replacement 
of oncosuppressor miRNAs provides an effective strategy 
against tumour heterogeneity, and the selective RNA-
based delivery system seems to be an excellent platform 
for a safe and effective targeting of tumours (Misso et al. 
Fig. 4 miR-34a is a direct transcriptional target of p53 and is a negative regulator of the tumourigenic properties of CD44hi lung CSCs. As is shown 
above, over expression of miR-34a could inhibit regeneration of LCSCs by repressing CD44 and the Notch and p53 pathways
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2014). Future work will aim to further clarify the underly-
ing mechanisms and intervene in its signalling pathways 
to find a cure for cancer.
miRNA‑200b regulates lung CSCs
Located at the miRNA-200b/c/429 gene cluster, miRNA-
200b, as an important member of miRNA-200 families, 
has the capability of repressing CSC growth and revers-
ing the EMT phenotype of CSCs (Iliopoulos et al. 2010; 
Sun et  al. 2012). The miRNA-200 family plays a key 
role in determining the epithelial phenotype by target-
ing zinc-finger transcriptional repressors ZEB1 or ZEB2 
(Comijn et al. 2001; Gregory et al. 2008; Park et al. 2008). 
In recent years, miR-200b was demonstrated to be a key 
regulator of chemoresistance and restoration and has 
been shown to significantly reverse chemoresistance 
of docetaxel (DTX)-resistant (lung adenocarcinoma) 
LAD cells by inducing cell cycle arrest and apoptosis 
enhancement (Feng et  al. 2012). Chen et  al. (2014) first 
showed that miR-200b functions as a tumour suppres-
sor in LAD CSCs both in  vitro and in  vivo. With fur-
ther study, they demonstrated that histone deacetylase 
1 (HDAC1) is involved in silencing of miR-200bthrough 
a Sp1-dependent mechanism. Inhibition of HDAC1 
could induce miR-200b expression, which significantly 
suppresses maintenance of CSCs and reverses chem-
oresistance of CSCs by regulating Suz-12-E-cadherin 
signalling (Chen et  al. 2014). CSCs have already been 
associated with chemotherapeutic failure in a variety of 
solid tumours. HDAC1/miR-200b/Suz-12/E-cadherin, 
which is involved in the regulation of CSC self-renewal, 
maintenance, tumourigenicity, growth and chemoresist-
ance, may be the key regulatory network in regulating 
CSC maintenance and chemoresistance in human LAD 
cells (Fig. 5). This discovery will provide a novel strategy 
for reversing chemoresistance of human LAD.
Fig. 5 Suppressor of zeste-12 (Suz-12) was identified as a direct and functional target of miR-200b. Histone deacetylase (HDAC) 1 repressed miR-
200b through a specificity protein (Sp) 1-dependent mechanism in which HDAC1 and Sp1 could bind to the miR-200b promoters (pro). Restoration 
ofmiR-200b by HDAC1 repression significantly suppressed CSC formation and reversed chemoresistance of CSCs by reducing Suz-12-E-cadherin
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Conclusions and perspectives
By targeting mRNAs for translational repression or 
degradation, miRNAs play important regulatory roles 
in animals and plants. As one of the most abundant 
classes of gene regulatory molecules in organisms, miR-
NAs likely influence the output of many protein-coding 
genes (Bartel 2004). There is mounting evidence to sug-
gest that miRNAs are involved in many fundamental 
cellular processes such as cell differentiation, prolifera-
tion, apoptosis, carcinogenesis and cancer progression 
(Winter et  al. 2009; Joshi et  al. 2014). Correlated with 
characteristic clinicopathological parameters in cancer 
subtypes and existing not only in tissue but also in body 
fluids, microRNAs are potential biomarkers for different 
cancer subtypes classified by origin, histology, or chem-
osensitivity (Lu et  al. 2005; Gilad et  al. 2008; Kishikawa 
et  al. 2015; Hollis et  al. 2015). Due to their characteris-
tic nature, microRNAs have a potential to be used for the 
development of diagnostics, prognostics, and targeted 
therapeutics.
In this review, the putting forward of the CSC theory 
gives researchers new ideas for recognizing the initiation 
of cancer and the regulation of cellular signalling in can-
cer and CSCs. Doubtless, CSCs do exist in tumours and 
drive tumour growth. Deeper research into CSCs will be 
a key to overcoming cancer. We have presented several 
regulatory mechanisms in CSCs, which mainly include 
miRNAs. In fact, since miRNAs were discovered in the 
1990s, they have been increasingly confirmed to play a 
critical role in carcinogenesis and cancer regulation. As 
there have been aberrant miRNA expression profiles 
identified in lung cancer, miRNAs could potentially be 
used as biomarkers in the diagnosis and classification 
of lung cancer instead of helical computed tomography 
(CT) or even pathological examination. Despite the fact 
that inspiring progress has been achieved in miRNA-
mediated gene activation, many questions remain to be 
further elucidated. For example, we do not know if dif-
ferent miRNAs interfere with each other in regulating 
tumour genesis and cancer progression. Moreover, the 
research in the CSC field is at an early stage. The specific-
ity and accuracy of lung CSC-associated miRNA signa-
tures need to be studied further.
This review aimed to summarize recent achieve-
ments in research on miRNAs regulating lung can-
cer stem cells. Accumulating evidence indicates that 
miRNAs play critical roles in lung CSCs. They can 
effectively control lung cancer stem cell cycles, pro-
liferation, apoptosis, immune response and differen-
tiation by regulating the signalling pathways of LCSCs. 
miR-145 can suppress the cancer stem cell-like proper-
ties of LCICs and the EMT process by targeting Oct4. 
Additionally, let-7 and microRNA-31 are critical for 
SP cells to preserve their stemness, as it was revealed 
that reduced miR-31 could inhibit cell proliferation by 
a cell cycle arrest in the G0/G1 phase, whereas reduced 
let-7 induced cell proliferation by accelerating the 
G1/S phase transition.miR-34a over expression inhib-
its NSCLC cell holoclone formation and clonogenic 
expansion in vitro and, importantly, tumour regenera-
tion in  vivo. The novel HDAC1/miR-200b/Suz-12/E-
cadherin pathway was confirmed to play an essential 
role in regulating maintenance, tumourigenicity and 
chemoresistance of CSCs in human LAD. However, 
further studies are needed for a more detailed under-
standing of the role of miRNAs in the biology of lung 
CSCs. The future further insights into the molecular 
mechanisms of tumourigenesis will provide novel treat-
ment strategies for patients with lung CSCs.
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